Shanghai Junshi Biosciences Co., Ltd. (SEHK: 1877)
Health Care · Biotechnology · CN
HK$17.65
-2.32% today · -34.7% 1Y
Shanghai Junshi Biosciences Co., Ltd. (SEHK: 1877) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.45B and employs 3,055 people.
Over the last twelve months the share price has lost 34.7%, trading between 15.25 and 30.80.
Tweenvest scores Shanghai Junshi Biosciences Co., Ltd. across four factors: quality 54/100, value 85/100, growth 100/100. Its strongest factor is growth.
1877 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.45B
- Revenue (TTM)
- $445.51M
- P/E
- —
- EPS
- -0.42
- Dividend yield
- —
- Beta (5Y)
- 0.52
- 52-week high
- HK$30.80
- 52-week low
- HK$15.25
- Avg volume (3M)
- —
- Shares outstanding
- 1.03B
- Employees
- 3,055
- Next earnings
- —
About Shanghai Junshi Biosciences Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
- ISIN
- CNE100003FF7
- Founded
- 2012
- Listed since
- Dec 24, 2018
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.90B | CN¥13.70 | -2.00% |
| 3SBio Inc.SEHK: 1530 | $4.79B | HK$15.07 | +0.53% |
| Dianthus Therapeutics, Inc.NasdaqCM: DNTH | $4.61B | $82.17 | -0.24% |
| Lin BioScience, Inc.TPEX: 6696 | $4.54B | NT$175.00 | -3.58% |
| Imeik Technology Development Co.,Ltd.SZSE: 300896 | $4.28B | CN¥95.03 | -0.16% |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd.SHSE: 688192 | $4.16B | CN¥59.95 | +3.34% |
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266 | $4.12B | CN¥104.25 | -5.23% |
| Tango Therapeutics, Inc.NasdaqGM: TNGX | $4.01B | $24.17 | +1.51% |
Figures last refreshed Oct 11, 2026.